We investigated a large number of acute myeloid leukemia (AML) samples (n=959) for the presence of the JAK2 V617F mutation. We found a low incidence of the mutation in these AML samples (1%). JAK2 V617F mutations clustered in AML samples with an aberrant karyotype (p<0.05). The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01). Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.
The oral PKC-Beta inhibitor enzastaurin (LY317615) inhibits proliferation and induces apoptosis in multiple myeloma cell lines / D. Verdelli, L. Nobili, K. Todoerti, L. Lombardi, S. Marmiroli, M. Civallero, M. Cosenza, J. Bertacchini, G. Lambertenghi Deliliers, A. Neri, S. Sacchi. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:Suppl. 3(2007), pp. 137-137. ((Intervento presentato al 41. convegno Congress of the Italian society of hematology tenutosi a Bologna nel 2007 [10.3324/haematol.10489].
The oral PKC-Beta inhibitor enzastaurin (LY317615) inhibits proliferation and induces apoptosis in multiple myeloma cell lines
D. Verdelli;L. Nobili;K. Todoerti;G. Lambertenghi Deliliers;A. Neri;
2007
Abstract
We investigated a large number of acute myeloid leukemia (AML) samples (n=959) for the presence of the JAK2 V617F mutation. We found a low incidence of the mutation in these AML samples (1%). JAK2 V617F mutations clustered in AML samples with an aberrant karyotype (p<0.05). The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01). Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
